Our study revealed the prognostic and metastatic effects of SPTBN2 in EEC, suggesting that SPTBN2 could serve as a prognostic biomarker and a target for metastasis therapy. This evidence concerns the gene SPTBN2 and exstrophy-epispadias complex.